Brought to you by 
Teva buys Copley for $220mm in cash
Sep 1999
Executive Summary
Israel's largest pharmaceutical company, Teva Pharmaceutical, is buying US generics company Copley for $220mm, paying $11 a share, a (pr)16.8% premium. Hoechst, which owns 52% of Copley, has agreed to sell its stake. Copley had sales last year of $133.5mm, and its net income was just over $10mm.
Deal Industry
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Acquisition
- Payment Includes Cash
- Full Acquisition
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Teva buys Copley for $220mm in cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice